Compass Therapeutics: Strong Cash Position and 2026 Clinical Catalysts Underpin Reiterated Buy Rating

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Compass Therapeutics, retaining the price target of $24.00.

Joseph Pantginis has given his Buy rating due to a combination of factors that, in his view, position Compass Therapeutics for a pivotal 2026. He sees 2026 as an important turning point, driven by a dense calendar of clinical data releases, trial initiations, and program expansions that could materially influence investor sentiment. He also underscores that Compass’s cash balance of roughly $209 million, with funding visibility into 2028, provides the company with sufficient resources to pursue its development plans without near‑term financing pressure. Central to his positive stance is the continued advancement of tovecimig, which has delivered encouraging activity in heavily pretreated metastatic colorectal cancer patients when compared with historical benchmarks.

Pantginis further highlights the breadth of Compass’s pipeline as a key element supporting his Buy rating. For CTX-8371, he points to ongoing cohort expansions in difficult post-checkpoint settings, with upcoming data that may open accelerated approval discussions in Hodgkin lymphoma and extend the asset’s reach beyond solid tumors. He also notes the planned start of first‑in‑human testing for CTX-10726 and a new Phase 2 study for CTX-471 in NCAM-expressing tumors, both of which add additional layers of optionality and upside. Taken together, the company’s strong balance sheet, multiple near- and mid-term catalysts, and the potential for meaningful clinical de-risking across several programs underpin his decision to reiterate a Buy recommendation on Compass Therapeutics.